The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•16 April 2026•

1 min read

Tivic Health Selected to Present Medical Tech to Department of War Tech Watch

A world map in golden tones with overlaid financial charts showing a downward trend, a large blue arrow pointing down, and falling circuit boards and text. Two screens display NASDAQ data.

Key Facts

1Tivic Health was selected to present Entolimod as a radiation countermeasure on May 7, 2026.

Tivic Health Systems, Inc. (Nasdaq: TIVC) has been selected to present its immunotherapeutic drug, Entolimod, and its oral transmucosal program to a U.S. defense technology initiative on May 7, 2026. The Department of War's Tech Watch program aims to identify emerging technologies with high-value defense and dual-use applications. The company's technology is being specifically evaluated as a countermeasure against radiation exposure. This selection provides significant validation for the micro-cap biotech firm and highlights its potential in the defense sector. Such government recognition often serves as a precursor to future federal contracts or specialized funding opportunities. Investors are closely monitoring the development as it could materially impact the company's long-term growth trajectory.